Skip to main content

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

Clinical Trial Grant
Duke Scholars

Awarded By

Amgen, Inc.

Start Date

September 8, 2025

End Date

September 18, 2030
 

Awarded By

Amgen, Inc.

Start Date

September 8, 2025

End Date

September 18, 2030